Clinical Trials

On May 14, 2013, the U. S. Food and Drug Administration approved erlotinib (Tarceva®, Astellas Pharma Inc.) for the first-line treatment of metast...

[Read the rest of this article...]

In written testimony to Congress on April 26, ASCO President Sandra M. Swain, MD, FACP, urged legislators to support a “strong federal investmen...

[Read the rest of this article...]

ASCO has submitted comments to the National Cancer Institute on its proposed NCI Community Oncology Research Program (NCORP), which would integrate three current NCI programs: the Community Clinical Oncology Program (CCOP), the Minority-Based CCOP (MB-CCOP), and the NCI Community Cancer Centers Program (NCCCP).

[Read the rest of this article...]

ASCO has released its new conflict of interest policy, ASCO Policy for Relationships With Companies, which updates its earlier policy in key ways that are designed to increase transparency in relationships with commercial interests.

[Read the rest of this article...]

The following profile of ASCO’s Cancer Research Committee is the second in a series of articles to help ASCO members better understand the role that volunteers serve and the critical work in which committee members are engaged.

[Read the rest of this article...]

ASCO and more than 150 other national organizations and institutions are supporting The Rally for Medical Research, on April 8 in Washington, D.C. The event will call on policymakers to make life-saving medical research funding a national priority.

[Read the rest of this article...]

In written testimony to Congress on March 15, ASCO President Sandra M. Swain, MD, FACP, urged legislators to support a “strong, stable federal investment” in cancer research to continue the progress being made in cancer prevention, detection, diagnosis and treatment.

[Read the rest of this article...]

ASCO, patient advocacy groups, and other provider organizations recently sent a letter to Centers for Medicare & Medicaid Services Acting Administrator Marilyn Tavenner urging the agency to correct a longstanding inequity in Medicare coverage for cancer patients wishing to participate in clinical trials.

[Read the rest of this article...]